Efficacy and safety of durvalumab plus tremelimumab for unresectable hepatocellular carcinoma in Thailand: A real-world multicenter observational study.
Krittiya Korphaisarn, Kosin Wirasorn, Suebpong Tanasanvimon, Kijjakom Thanasombunsukh, Kunlatida Maneenil, Jirawat Thanestada, Nattaya Teeyapun, Jarin Chindaprasirt, Chirawadee Sathitruangsak, Teerada Siripoon, Phannin Tiraswasdichai, Chanchai Charonpongsuntorn, Passakorn Wanchaijiraboon, Wannisa Laosuangkoon, Patrapim Sunpaweravong, Charuwan Akewanlop,539
Background:
Durvalumab plus tremelimumab (Durva/Treme) andatezolizumab plus bevacizumab are preferable first-line therapy for unresectable hepatocellular carcinoma (uHCC). This study aimed to evaluate the efficacy and safety of Durva/Treme in real world setting.
Methods:
Fifty patients with uHCC who enrolled in the expanded access program (EAP) for Durva/Treme as the first-line treatment from 12 centers in Thailand were included. Analysis was assessed for objective response rate (ORR), survival, and adverse events. We also compared data with the HIMALAYA study.
Results:
Median follow-up time was 9.8 months. There were 24 patients alive and 26 patients deceased. The median age was 62 years. Majority of the patients were male (80%). Hepatitis B, C and non-viral cause were identified in 44%, 30%, and 26%, respectively. Ninety-two percent of patients had Child-Pugh A, while 8% had Child-Pugh B(7). Macrovascular invasion was found in 24% of cases. The full data on efficacy and safety were summarized in table below.
Conclusions:
To date,this is the largest real-world data of Durva/Treme in the first-line treatment of uHCC. Our study demonstrated that Durva/Treme was effective but had lower ORR and higher liver toxicities than what reported in the HIMALAYA study.